ERBB2 and breast carcinoma: Subgroup analysis in different breast cancer subtypes revealed thathigh GZMK expression could improve RFS in TNBC, Luminal A, Luminal B, and HER2-positive breast cancer, with statistically significant differences (P < 0.05) (Figures S4B–E).